Dihydro-alpha-ergocryptine is a nootropic with an unknown mechanism of action indicated in individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity. Alpha-dihydroergocryptine is usually referred to the mixture of the alpha and beta dihydroergocryptine.
- Mechanism
- Curator reviewed · 2 references
Alpha-dihydroergocryptine is an established high-affinity ligand to alpha 1 and alpha 2 adrenoreceptors in a number of tissues as well as a dopamine ligand in the brain. It is reported to be a potent agonist of the dopamine D2 receptor and a partial agonist of the dopamine receptors D1 and D3. To know more about the ergoloid mesylate mixture please visit DB01049 and to know more about the isomer please visit DB11275.
- Primary indication
- Alpha-dihydroergocryptine has been studied for the early treatment of Parkinson disease as well as for its use in migraine prophylaxis, treatment of low blood pressure and peripheral vascular disorder.Curator reviewed · 3 structured indications
- Formula / weight
- C32H43N5O5 · 577.726 g/mol (avg)
- First approval
- United States, 1980
- Also known as
- alpha-Dihydroergocriptine
Resolves to
PBUNVLRHZGSROC-VTIMJTGVSA-NSMILES[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)CWhat you can answer from here — as of September 13, 2026
Which drugs share a target with Dihydro-alpha-ergocryptine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account